Agentix Corp.

AGTX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2019 FY2018
Operating Activities
Net Income $-485.6K $-567.0K $-585.2K $-1.4M $-2.6M $-1.3M $-132.7K $-42.8M
Depreciation & Amortization — — — — — — — —
Depreciation — — — — — — $140 $264
Amortization — — — — — — — —
Stock-Based Compensation — — — — — — — —
Net Cash from Operating Activities $-108.5K $-125.1K $-110.4K $-88.5K $-25.2K $-421.0K $-62.0K $-51.6K
Investing Activities
Capital Expenditures — — — — — — — —
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $0 $0 $0 $0 $0 $0 — —
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $110.5K $100.0K $93.0K $100.0K $0 $180.0K $60.0K $50.0K
Net Change in Cash $-3.7K $-2.1K $-5.8K $12.2K $-25.2K $-241.0K — $-1.6K
Free Cash Flow — — — — — — — —
← Newer Page 1 of 2 Older →